142 related articles for article (PubMed ID: 11906774)
21. Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children.
Englund JA; Karron RA; Cunningham CK; Larussa P; Melvin A; Yogev R; Handelsman E; Siberry GK; Thumar B; Schappell E; Bull CV; Chu HY; Schaap-Nutt A; Buchholz U; Collins PL; Schmidt AC;
Vaccine; 2013 Nov; 31(48):5706-12. PubMed ID: 24103895
[TBL] [Abstract][Full Text] [Related]
22. Attenuating mutations in the P/C gene of human parainfluenza virus type 1 (HPIV1) vaccine candidates abrogate the inhibition of both induction and signaling of type I interferon (IFN) by wild-type HPIV1.
Van Cleve W; Amaro-Carambot E; Surman SR; Bekisz J; Collins PL; Zoon KC; Murphy BR; Skiadopoulos MH; Bartlett EJ
Virology; 2006 Aug; 352(1):61-73. PubMed ID: 16750233
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children.
Karron RA; Thumar B; Schappell E; Surman S; Murphy BR; Collins PL; Schmidt AC
Vaccine; 2012 Jun; 30(26):3975-81. PubMed ID: 22178099
[TBL] [Abstract][Full Text] [Related]
24. Determinants of the host range restriction of replication of bovine parainfluenza virus type 3 in rhesus monkeys are polygenic.
Skiadopoulos MH; Schmidt AC; Riggs JM; Surman SR; Elkins WR; St Claire M; Collins PL; Murphy BR
J Virol; 2003 Jan; 77(2):1141-8. PubMed ID: 12502830
[TBL] [Abstract][Full Text] [Related]
25. Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates.
Schmidt AC; McAuliffe JM; Huang A; Surman SR; Bailly JE; Elkins WR; Collins PL; Murphy BR; Skiadopoulos MH
J Virol; 2000 Oct; 74(19):8922-9. PubMed ID: 10982335
[TBL] [Abstract][Full Text] [Related]
26. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
[TBL] [Abstract][Full Text] [Related]
27. Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates.
Liu X; Liang B; Liu X; Amaro-Carambot E; Surman S; Kwong PD; Graham BS; Collins PL; Munir S
PLoS One; 2020; 15(2):e0228572. PubMed ID: 32045432
[TBL] [Abstract][Full Text] [Related]
28. Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3' genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates.
Nolan SM; Skiadopoulos MH; Bradley K; Kim OS; Bier S; Amaro-Carambot E; Surman SR; Davis S; St Claire M; Elkins R; Collins PL; Murphy BR; Schaap-Nutt A
Vaccine; 2007 Aug; 25(34):6409-22. PubMed ID: 17658669
[TBL] [Abstract][Full Text] [Related]
29. A replication-incompetent influenza virus bearing the HN glycoprotein of human parainfluenza virus as a bivalent vaccine.
Kobayashi H; Iwatsuki-Horimoto K; Kiso M; Uraki R; Ichiko Y; Takimoto T; Kawaoka Y
Vaccine; 2013 Dec; 31(52):6239-46. PubMed ID: 24144478
[TBL] [Abstract][Full Text] [Related]
30. Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.
Liang B; Ngwuta JO; Surman S; Kabatova B; Liu X; Lingemann M; Liu X; Yang L; Herbert R; Swerczek J; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Collins PL; Munir S
J Virol; 2017 Aug; 91(15):. PubMed ID: 28539444
[TBL] [Abstract][Full Text] [Related]
31. Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro.
McAuliffe JM; Surman SR; Newman JT; Riggs JM; Collins PL; Murphy BR; Skiadopoulos MH
J Virol; 2004 Feb; 78(4):2029-36. PubMed ID: 14747567
[TBL] [Abstract][Full Text] [Related]
32. Current status of vaccines for parainfluenza virus infections.
Sato M; Wright PF
Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S123-5. PubMed ID: 18820572
[TBL] [Abstract][Full Text] [Related]
33. PIV-3 vaccine National Institutes of Health/Aviron.
Jones T
Curr Opin Investig Drugs; 2001 Jul; 2(7):890-2. PubMed ID: 11757785
[TBL] [Abstract][Full Text] [Related]
34. The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys.
Durbin AP; Wyatt LS; Siew J; Moss B; Murphy BR
Vaccine; 1998 Aug; 16(13):1324-30. PubMed ID: 9682397
[TBL] [Abstract][Full Text] [Related]
35. Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes.
Pletnev AG; Bray M; Hanley KA; Speicher J; Elkins R
J Virol; 2001 Sep; 75(17):8259-67. PubMed ID: 11483771
[TBL] [Abstract][Full Text] [Related]
36. Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults.
Tang RS; Spaete RR; Thompson MW; MacPhail M; Guzzetta JM; Ryan PC; Reisinger K; Chandler P; Hilty M; Walker RE; Gomez MM; Losonsky GA
Vaccine; 2008 Nov; 26(50):6373-82. PubMed ID: 18822334
[TBL] [Abstract][Full Text] [Related]
37. Influence of antigen insertion site and vector dose on immunogenicity and protective capacity in Sendai virus-based human parainfluenza virus type 3 vaccines.
Mason JN; Elbahesh H; Russell CJ
J Virol; 2013 May; 87(10):5959-69. PubMed ID: 23514887
[TBL] [Abstract][Full Text] [Related]
38. Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1.
Tao T; Durbin AP; Whitehead SS; Davoodi F; Collins PL; Murphy BR
J Virol; 1998 Apr; 72(4):2955-61. PubMed ID: 9525616
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of attenuation, immunogenicity and efficacy of a bovine parainfluenza virus type 3 (PIV-3) vaccine and a recombinant chimeric bovine/human PIV-3 vaccine vector in rhesus monkeys.
Pennathur S; Haller AA; MacPhail M; Rizzi T; Kaderi S; Fernandes F; Bicha L; Schickli JH; Tang RS; Chen W; Nguyen N; Mathie S; Mehta H; Coelingh KL
J Gen Virol; 2003 Dec; 84(Pt 12):3253-3261. PubMed ID: 14645907
[TBL] [Abstract][Full Text] [Related]
40. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
